Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases.
Cholestatic hepatitis developed in two patients while they were receiving erythromycin ethylsuccinate. Both patients had received the drug without apparent problem within two months of the episode of drug-related cholestatic injury. In both, there was complete resolution of the hepatic injury upon withdrawal of the drug. Erythromycin ethylsuccinate should be added to the list of drugs causing cholestatic hepatitis.
D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis* / Q000473:pathology; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced* / Q000473:pathology; D004917:Erythromycin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015643:Erythromycin Ethylsuccinate; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D007565:Jaundice / Q000139:chemically induced; D008099:Liver / Q000648:ultrastructure; D008875:Middle Aged; D000637:Transaminases / Q000097:blood
D015643:Erythromycin Ethylsuccinate; D004917:Erythromycin; D000637:Transaminases